Revium Rx. (RVRC)

Market Cap	101.42M +234.0%
Revenue (ttm)	n/a
Net Income	-13.54M
EPS	-0.22
Shares Out	60.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30
Open	1.670
Previous Close	1.670
Day's Range	1.670 - 1.670
52-Week Range	0.520 - 1.670
Beta	-0.76
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Revium Rx.

Revium Rx. operates as a pre-clinical stage biopharmaceutical company focused on the development of nanoparticle-based therapies in the United States. The company develops lipid-based platforms for a variety of uses including antimicrobial resistance and solid tumors; specializes in infectious diseases, including antibiotic-resistant infections, solid tumors, and vaccination; and develops nano-liposomal particles (NLP) based pharmaceutical candidates. It also offers Nano-Mupirocin, a NLP-based formulation of potent antibiotic mupirocin. In addi...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 1997
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: RVRC

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 10, 2026

Data Sources Report a data error